Published

MSR20 Challenges in the Development of Economic Evaluations for Psychedelics in Treatment of Depression

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Value in Health
Date: 2022-06-24
Source: OpenAlex
DOI: 10.1016/j.jval.2022.04.1227
PubMed: Unavailable

Authors

J Schneider JP Cooper S Davies K Beltran

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Addiction Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

MSR20 Challenges in the Development of Economic Evaluations for Psychedelics in Treatment of Depression2022-06-24

Related papers

Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin ServicesJAMA Network Open · 2026-08-19 Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health SymptomsJournal of Drug Issues · 2026-07-01 Psilocybin and Mental Health Outcomes: Scoping Review with ☸️SAIMSARASAIMSARA Journal · 2026-06-15 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic improvements: two case studies from JamaicaFrontiers in Psychiatry · 2026-07-29 PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEWInternational Journal of Innovative Technologies in Social Science · 2026-06-24 Reporting practices in psilocybin-assisted therapy trials for depression: A descriptive review and temporal overviewJournal of Psychedelic Studies · 2026-07-13 Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health careTranslational Psychiatry · 2026-06-23